GESTIÓN EN SALUD PÚBLICA: Fact Sheet for Healthcare Providers: Atellica® IM SARS-CoV-2 Total (COV2T) May 29, 2020; Siemens Healthcare Diagnostics Inc.

miércoles, 3 de junio de 2020

Fact Sheet for Healthcare Providers: Atellica® IM SARS-CoV-2 Total (COV2T) May 29, 2020; Siemens Healthcare Diagnostics Inc. | NLM

Disaster Information Management Research Center | NLM

Disaster Information and Emergency Response

Fact Sheet for Healthcare Providers: Atellica® IM SARS-CoV-2 Total (COV2T) May 29, 2020; Siemens Healthcare Diagnostics Inc.

05/29/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 5/29/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Atellica® IM SARS-CoV-2 Total (COV2T) assay, which received an Emergency Use Authorization from the Food and Drug Administration on May 29, 2020. The Atellica® IM SARS-CoV-2 Total (COV2T) assay is authorized for the detection of antibodies to SARS-CoV-2 in human serum and plasma. (PDF)